How to improve access to therapy?
around the world table

Poland

Robert Flisiak

Department of Infectious Diseases and Hepatology
Medical University in Białystok, Poland

Paris Hepatitis Conference
Paris, 12-13 January 2015

Disclosures

Advisor and/or speaker for

AbbVie, Bristol-MyersSquibb, Gilead, Janssen, Merck, Novartis, Roche

Situation of hepatitis C in Poland

Prevalence of anti-HCV and HCV RNA



Risk factors for anti-HCV positivity

	OR (95% CI)	*P*
Sex male vs. female	1.74 (1.32, 2.29)	<0.001
Age >median	0.77 (0.59, 1.02)	0.07
Number of hospital admissions>median	1.75 (1.31, 2.34)	<0.001
Endoscopic procedures	–	>0.1
Dialysis	–	>0.1
Surgical procedures	–	>0.1
Blood transfusions before 1992	2.88 (2.08, 3.98)	<0.001
History of tattooing and/or piercing	–	>0.1
Intravenous drug use	6.13 (3.8, 10.0)	<0.001

Age and gender



Fibrosis stage



HCV genotypes



IL28B genotypes



Flisiak R, et al. Eur J Gastroent Hepatol 2011; 23: 1213–1217.
Godzik P, et al. Epidemiol Rev 2012; 66: 575-580.

Crucial problems that complicate the optimal management of patients

1) Elastography is not allowed by National Health Fund (NFZ) for enrollment to reimbursed treatment of genotype 1 infected patients (liver biopsy necessary)



Genetic selection for
triple therapy (BOC or TVR)
(reimbursed for 20% HCV population only)

3) No reimbursement of
- IFN based treatment with SOF, SMV or DCV
- IFN-free regimen
  - 3D (PRV/OBV/DSV) - ongoing managed access program
  - DCV/ASV - access expected
  - SOF/LDV - not offered
  - combination of SOF with SMV or DCV not allowed ...

ng lasting reimbursement approval procedures by regulatory authorities.
for BOC and TVR it took →20 months (approved in mid 2013)

How to improve access to therapy

- Inclusion of anti-HCV testing in the set of reimbursed procedures for GPs.
- Exclusion from the HCV therapy reimbursement program (covered by NFZ).
  - IL28B based genetic selection
  - obligatory liver biopsy
- Improvement of regulations for reimbursement approval, to speed up procedures.
- Need of „compassionate use regulations".



Flisiak R i wsp. Eur J Gastro Hepatol 2015; 27: 70-76.